Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Regeneron's Libtayo receives CHMP positive opinion for alternative every-six-week dosing schedule
Monoclonal antibody, oncology, regulatory - Read more

FDA approves Opus Genetics' Ryzumvi (phentolamine) for presbyopia following Ph3 success, marking second label indication
Small molecule, ophthalmology, alpha-adrenergic antagonist, presbyopia, phentolamine - Read more

Paradromics, Siemens Healthineers collaborate to develop multimodal imaging platform supporting brain-computer interfaces
Research collaboration, diagnostics, neurological, digital health, brain-computer interfaces - Read more

Roche, Hansoh Pharmaceutical expand ADC alliance with broad portfolio deal, $400M upfront, $15B potential
Licensing deal, oncology, antibody-drug conjugate, milestone payments, royalties - Read more

Ekalia, Telix Pharmaceuticals collaborate to accelerate Astatine-211 production infrastructure in the United States
Manufacturing agreement, oncology, radiopharmaceuticals, targeted alpha therapy, joint venture - Read more

Algorae Pharmaceuticals, Umedica Laboratories sign MOU and licence supply agreement for Australian pharmaceutical market
Licensing deal, manufacturing agreement, small molecule, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Disc Medicine's (bitopertin) Ph3 trial meets all endpoints for erythropoietic protoporphyria, paving way for FDA resubmission
Small molecule, metabolic, erythropoietic protoporphyria, glycine transporter 1 inhibitor, rare disease - Read more

AbbVie's ABBV-466 (trosunilimab + Skyrizi) combo beats Skyrizi monotherapy in Ph2 Crohn's disease trial
Antibody, autoimmune, monoclonal antibody, Crohn's disease, combination therapy, IL-23 inhibitor - Read more

Veradermics' VDPHL01 (minoxidil) meets Ph3 endpoints, improving hair coverage in male androgenetic alopecia
Small molecule, dermatological, extended-release formulation, androgenetic alopecia, minoxidil, pattern hair loss - Read more

OSE Immunotherapeutics' Tedopi (OSE2101) meets primary endpoint in Ph2 trial for metastatic non-small cell lung cancer
Vaccine, cancer, peptide vaccine, non-small cell lung cancer, combination therapy, anti-PD1 - Read more

Nouscom raises $135M Series D for pivotal cancer-preventing vaccine trial in Lynch syndrome
Cancer vaccine, oncology, Lynch syndrome, rare disease, immunotherapy, clinical-stage - Read more

Flavii Therapeutics raises €843K ($947.4K), advancing epigenetic therapies for neurological disorders
Neurological, small molecule, epigenetics, preclinical, neurodegeneration - Read more

Microbiotica raises $48M Series C to advance MB310 into Phase 2 ulcerative colitis trials
Clinical-stage, microbiome therapeutics, ulcerative colitis, autoimmune, oral drug delivery - Read more

Sanofi breaks ground on new Frankfurt insulin manufacturing facility, targeting full production by 2032
Insulin, diabetes, operational, manufacturing - Read more

Merck KGaA acquires Silence Therapeutics for $1.3B, gaining promising siRNA blood cancer drug divesiran
siRNA, oncology, rare disease, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

TWi Biotechnology's AC-203 Ph2/3 trial misses primary endpoint in epidermolysis bullosa simplex
Small molecule, skin disease, epidermolysis bullosa, pain management, phase 2/3 trial - Read more

Enlivex cuts 60% of workforce, scraps preclinical R&D, slashes exec salaries to fund osteoarthritis trial
Cell therapy, musculoskeletal, cost reduction, operational - Read more

Roche pauses future Germany investments amid healthcare cost-cutting policies, joining pharma industry pullback
Pharmaceutical investment, healthcare policy, strategic, financial, competitive - Read more

China proposes export restrictions on AI, biotech technologies, potentially impacting global biopharma licensing deals
Cell and gene therapy, rare disease, export controls, strategic - Read more

Novartis halts Ph2 study of Fabhalta (iptacopan) in lupus nephritis, citing strategic reasons over safety or efficacy concerns
Small molecule, autoimmune, complement inhibitor, lupus nephritis, factor B inhibitor - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here